CN213293077U - Freezing device - Google Patents
Freezing device Download PDFInfo
- Publication number
- CN213293077U CN213293077U CN202021041774.6U CN202021041774U CN213293077U CN 213293077 U CN213293077 U CN 213293077U CN 202021041774 U CN202021041774 U CN 202021041774U CN 213293077 U CN213293077 U CN 213293077U
- Authority
- CN
- China
- Prior art keywords
- liquid inlet
- cell
- sealing layer
- main
- freezing chamber
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 238000007710 freezing Methods 0.000 title claims abstract description 25
- 230000008014 freezing Effects 0.000 title claims abstract description 25
- 239000007788 liquid Substances 0.000 claims abstract description 39
- 238000005138 cryopreservation Methods 0.000 claims abstract description 16
- 238000005070 sampling Methods 0.000 claims abstract description 10
- 238000007789 sealing Methods 0.000 claims description 43
- 239000011148 porous material Substances 0.000 claims description 5
- 238000002659 cell therapy Methods 0.000 abstract description 6
- 210000004027 cell Anatomy 0.000 description 62
- 239000003814 drug Substances 0.000 description 16
- 229940079593 drug Drugs 0.000 description 9
- 238000004519 manufacturing process Methods 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 239000000523 sample Substances 0.000 description 6
- 238000003860 storage Methods 0.000 description 6
- 230000000694 effects Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 230000008569 process Effects 0.000 description 4
- 238000004113 cell culture Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000005516 engineering process Methods 0.000 description 3
- 230000014759 maintenance of location Effects 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 238000002360 preparation method Methods 0.000 description 3
- 238000002560 therapeutic procedure Methods 0.000 description 3
- 238000005054 agglomeration Methods 0.000 description 2
- 230000002776 aggregation Effects 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000011134 hematopoietic stem cell transplantation Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- 239000000565 sealant Substances 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 238000013459 approach Methods 0.000 description 1
- 230000004888 barrier function Effects 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 230000003394 haemopoietic effect Effects 0.000 description 1
- 210000000777 hematopoietic system Anatomy 0.000 description 1
- 210000002865 immune cell Anatomy 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 238000001802 infusion Methods 0.000 description 1
- 210000002901 mesenchymal stem cell Anatomy 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 238000000746 purification Methods 0.000 description 1
- 238000011084 recovery Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000000130 stem cell Anatomy 0.000 description 1
- 238000009168 stem cell therapy Methods 0.000 description 1
- 238000011476 stem cell transplantation Methods 0.000 description 1
- 238000009580 stem-cell therapy Methods 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
Images
Abstract
The utility model provides a freeze and deposit device, including following structure: the freezing chamber comprises a plurality of independent small chambers, each independent small chamber comprises a freezing chamber, a sampling port is arranged at the upper end of each freezing chamber, and a liquid inlet is arranged at the lower end of each freezing chamber; the liquid inlet channel is connected with the liquid inlet into a whole, and the independent small chambers are arranged on the liquid inlet channel; one side of the liquid inlet channel is provided with a main liquid inlet, and a main pipeline is connected to the main liquid inlet. The provided cryopreservation device can be used for filling, storing, freezing, recovering and using various cell therapy products.
Description
Technical Field
The utility model relates to a medical instrument, specific theory relates to a freeze and deposit device that is used for biological product to gather, store, transport.
Background
Cell transplantation therapy is an advanced medical technology, and brings hope for the treatment of some difficult and complicated diseases. Hematopoietic stem cell transplantation, stem cell transplantation therapy, and immunocyte therapy can be roughly classified according to the cell type. Hematopoietic stem cell transplantation can reconstruct hematopoietic and immune systems for patients, and cell transplantation of stem cell therapy including mesenchymal stem cells, endothelial progenitor cells and the like can also bring remarkable effects for disease treatment. Immune cell therapy is a safe and effective therapeutic approach by enhancing immunity and killing pathogens and tumor cells.
Cell therapy drugs have been rapidly developed in recent two years, some of them have been on the market, and a large number of them are also in clinical trials. The effectiveness of cell therapy drugs is determined by the cell preparation process, the stability of cell drug storage. The main process comprises the steps of donor screening, tissue collection, transportation, cell separation, purification, cell medicine preparation, cell medicine storage, transportation and the like, wherein the cell medicine storage is a key technology which directly influences the curative effect. The operation optimization of the preparation, storage and transportation processes of cell medicines, the convenience of recovery operation and infusion operation when the product is used and the guarantee of the whole process and flow from pollution are all important aspects of the production and quality of cell treatment medicines.
In clinical application of cells, in order to maintain the activity of the cells, ensure the convenience of operation and reduce the pollution rate, the product is required to be prepared, stored and recovered, and the same container is used in the whole process of use.
Patent No. CN205418605U provides an integrated cryopreservation bag for biological samples, which is convenient for large-scale storage of cryopreservation bag samples even if small amount of samples are subpackaged.
Patent No. CN206699255U provides a cell cryopreservation bag for storing, freezing, and resuscitating various cells, and storing cells directly used for therapeutic patient reinfusion, which can satisfy multiple resuscitations and different functions of cells from the same donor.
The difference between the cell therapy medicine and the traditional medicine lies in that the main component is cells, the diameters of the cells have certain difference, and a certain cell agglomeration phenomenon may exist in later-stage operation, the cells are directly injected into a freezing bag in patents CN205418605U or CN206699255U, the consistency of products is difficult to ensure, and the cell agglomeration can generate certain influence on later-stage treatment.
Disclosure of Invention
To the problem that prior art exists, the utility model provides a freeze and deposit device.
The utility model provides a freeze and deposit device includes following technical characteristic:
freezing device that deposits includes following structure: the freezing chamber comprises a plurality of independent small chambers, each independent small chamber comprises a freezing chamber, a sampling port is arranged at the upper end of each freezing chamber, and a liquid inlet is arranged at the lower end of each freezing chamber; the liquid inlet channel is connected with the liquid inlet into a whole, and the independent small chambers are arranged on the liquid inlet channel; one side of the liquid inlet channel is provided with a main liquid inlet, and a main pipeline is connected to the main liquid inlet.
Preferably, the main pipeline can be fused by a heat sealing instrument after filling is finished, and the fused main pipeline is stored in liquid nitrogen for detection and sample retention.
Preferably, the number of said individual cells is 3-12.
The number of individual chambers can be freely selected depending on the cell production process, and may be, for example: 3, 4, 5, 6, 8, 10, 12. The independent small chambers are filled with cell medicines through the liquid inlet channels, so that the risk caused by manual operation is reduced, and the production efficiency of the cell medicines is improved.
Preferably, be provided with the cell strainer on the trunk line, the aperture of cell strainer is: 30-200 μm. The cell filter screen mainly acts as a barrier to larger cell clumps from entering the cryopreservation chamber, affecting the quality of cell products. The cell strainer can be determined according to the size of cells and the cell culture process, so as to intercept cell aggregates with an ultra-large diameter, for example, the pore size of the cell strainer can be: 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 11 μm, 120 μm, 130 μm, 140 μm, 150 μm, 160 μm, 170 μm, 180 μm, 190 μm or 200 μm.
Preferably, a pipe clamp is arranged on the main pipe.
Preferably, a sample reserving opening is formed in the main pipeline.
Preferably, the end part of the main pipeline is provided with a spiral connector, and a cover cap with a matched size is arranged outside the spiral connector. The screw interface may be connectable to a syringe. The spiral interface can be tightly connected with the injector to ensure the tightness and safety of the interface and reduce the liquid leakage and pollution in operation.
Preferably, the sampling port is provided with a sealing cap.
Preferably, the sealing cap includes a first sealing layer, a connection portion, and a second sealing layer disposed on the sampling port.
Preferably, the connecting portion is cylindrical or rectangular, the upper section of the connecting portion is connected with the first sealing layer, and the lower end of the connecting portion is connected with the second sealing gasket. The first sealing layer directly isolates the inside of the small chamber, the second sealing layer is another sealing structure on the basis of the first sealing layer, and the second sealing layer can be directly inserted by an injector in use except secondary isolation, so that the safety of products in use is guaranteed. The first sealing layer and the second sealing layer are in a sterile state.
Preferably, each individual cell of the plurality of individual cells is separable by heat sealing.
Compared with the prior art, the beneficial effects of the utility model reside in that:
the freezing device that provides can be used for the filling of various cell therapy products, the storage, freezes, revives and uses, and the number of independent cell can carry out the free choice according to cell production technology, carries out the filling of cell medicine through same pipeline, has reduced the risk that manual operation brought, has improved the production efficiency of cell medicine. The main pipeline can be fused by a heat sealing instrument after being filled, and can be stored in liquid nitrogen for detection and sample reservation. The cell filter screen can determine the aperture according to the size of cells and a cell culture process and is used for intercepting cell aggregates with overlarge diameters, and the spiral interface can be tightly connected with the injector so as to ensure the tightness and safety of the interface and reduce the liquid leakage and pollution in operation. The outer layer sealing layer of the sampling port can be pulled out after the cells are recovered, and the syringe is adopted to directly absorb and prepare the product, so that the operation steps are reduced, and the clinical use is convenient.
Drawings
FIG. 1 is a schematic structural diagram of a cryopreservation apparatus according to an embodiment of the present application;
FIG. 2 is a schematic representation of the isolated cell after fusing;
fig. 3 is a schematic structural view of a sealing cover according to an embodiment.
The device comprises an independent small chamber-10, a freezing chamber-11, a sealing cover-12, a first sealing layer-121, a second sealing layer-122, a connecting part 123, a liquid inlet channel-20, a main liquid inlet-21, a main pipe-30, a pipe clamp-31, a cell filter screen-32, a sample reserving port-33 and a spiral connector-34.
Detailed Description
The technical solution of the present invention is further explained by the following embodiments. It should be understood by those skilled in the art that the examples are only for the understanding of the present invention and should not be construed as the specific limitations of the present invention.
Referring to fig. 1 and 2, the cryopreservation apparatus includes the following structure: the freezing chamber comprises a plurality of independent small chambers 10, wherein each independent small chamber 10 comprises a freezing chamber 11, a sampling port is arranged at the upper end of each freezing chamber 11, and a liquid inlet is arranged at the lower end of each freezing chamber 11; the liquid inlet channel 20, the liquid inlet channel 20 and the liquid inlet are connected into a whole, and the independent small chambers 10 are arranged on the liquid inlet channel 20; one side of the liquid inlet channel 20 is provided with a main liquid inlet 21, and the main liquid inlet 21 is connected with a main pipe 30.
In some embodiments, the main pipe 30 may be fused after filling by using a heat sealing instrument, and the fused main pipe 30 is stored in liquid nitrogen for detection and sample retention.
In some embodiments, the number of individual cells 10 is 3-12. The number of individual chambers 10 can be freely selected according to the cell production process, and may be, for example: 3, 4, 5, 6, 8, 10, 12. The independent small chambers 10 are filled with cell medicines through the liquid inlet channels 20, so that the risk caused by manual operation is reduced, and the production efficiency of the cell medicines is improved.
In some embodiments, a cell strainer 32 is disposed on the main conduit 30, and the pore size of the cell strainer 32 is: 30-200 μm. The primary function of the cell strainer 32 is to block larger cell clumps from entering the cryopreservation chamber, affecting cell product quality. The cell strainer 32 may have a pore size determined according to the size of the cells and the cell culture process, so as to intercept cell aggregates with an excessively large diameter, for example, the pore size of the cell strainer 32 may be: 30 μm, 40 μm, 50 μm, 60 μm, 70 μm, 80 μm, 90 μm, 100 μm, 11 μm, 120 μm, 130 μm, 140 μm, 150 μm, 160 μm, 170 μm, 180 μm, 190 μm or 200 μm.
In some embodiments, a conduit clip 31 is provided on the main conduit 30.
In some embodiments, sample retention port 33 is provided on main conduit 30.
In some embodiments, the end of the main conduit 30 is provided with a screw interface 34, and a cap with a suitable size is provided outside the screw interface 34. The screw interface 34 may be connected to a syringe. The screw port 34 can be tightly connected to the syringe to ensure the tightness and safety of the port and reduce the occurrence of liquid leakage and contamination during operation.
In some embodiments, the thief hatch is provided with a sealing cap 12.
Referring to fig. 3, the sealing cap 12 includes a first sealing layer 121, a connection part 123, and a second sealing layer 122, and the second sealing layer 122 is disposed on the sampling port.
In some embodiments, the connection portion 123 has a cylindrical or rectangular shape, an upper section of the connection portion 123 is connected to the first sealing layer 121, and a lower end of the connection portion 123 is connected to the second sealing pad. The first sealing layer 121 directly isolates the interior of the small chamber, the second sealing layer 122 is another sealing structure on the basis of the first sealing layer 121, and the second sealing layer 122 can be directly inserted by a syringe in use besides secondary isolation, so that the safety of the product in use is guaranteed. The first sealant 121 and the second sealant 122 are in a sterile state therebetween.
In some embodiments, each individual cell 10 of the plurality of individual cells 10 may be separated by heat sealing.
Although the embodiments of the present invention have been described above with reference to the accompanying drawings, the present invention is not limited to the above-described embodiments and application fields, and the above-described embodiments are illustrative, instructive, and not restrictive. Those skilled in the art, having the benefit of this disclosure, may effect numerous modifications thereto without departing from the scope of the invention as defined by the claims appended hereto.
Claims (9)
1. Freezing device that deposits, its characterized in that includes following structure: the freezing chamber comprises a plurality of independent small chambers, each independent small chamber comprises a freezing chamber, a sampling port is arranged at the upper end of each freezing chamber, and a liquid inlet is arranged at the lower end of each freezing chamber; the liquid inlet channel is connected with the liquid inlet into a whole, and the independent small chambers are arranged on the liquid inlet channel; one side of the liquid inlet channel is provided with a main liquid inlet, and a main pipeline is connected to the main liquid inlet.
2. The cryopreservation device of claim 1, wherein a cell strainer is arranged on the main pipeline, and the pore diameter of the cell strainer is as follows: 30-200 μm.
3. The cryopreservation device of claim 1, wherein a pipe clamp is provided on the main pipe.
4. The cryopreservation device of claim 1, wherein a sample retaining port is arranged on the main pipeline.
5. The cryopreservation device of claim 1, wherein a spiral connector is arranged at the end of the main pipeline, and a cap with a size matched with the spiral connector is arranged outside the spiral connector.
6. The cryopreservation device of claim 1, wherein the sampling port is provided with a sealing cap.
7. The cryopreservation device of claim 6, wherein the sealing cap comprises a first sealing layer, a connecting portion and a second sealing layer, the second sealing layer being disposed on the sampling port.
8. The cryopreservation device of claim 7, wherein the connecting part is cylindrical or rectangular in shape, an upper section of the connecting part is connected with the first sealing layer, and a lower end of the connecting part is connected with the second sealing layer.
9. The cryopreservation device of claim 1 wherein each of the plurality of individual cells is separable by heat sealing.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202021041774.6U CN213293077U (en) | 2020-06-09 | 2020-06-09 | Freezing device |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202021041774.6U CN213293077U (en) | 2020-06-09 | 2020-06-09 | Freezing device |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CN213293077U true CN213293077U (en) | 2021-05-28 |
Family
ID=76017631
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202021041774.6U Active CN213293077U (en) | 2020-06-09 | 2020-06-09 | Freezing device |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN213293077U (en) |
-
2020
- 2020-06-09 CN CN202021041774.6U patent/CN213293077U/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US9182328B2 (en) | Apparatus and method for processing biological material | |
| CN213293077U (en) | Freezing device | |
| CN201759859U (en) | Liquid dispersing device for medical use | |
| CN107261252A (en) | Multifunctional disposable transfusion device | |
| CN209270481U (en) | Infusion apparatus | |
| CN105919805B (en) | Dispensation injection needle with bi-directional filtered function | |
| CN211214749U (en) | Medical treatment filter that dispenses | |
| CN105816933A (en) | Transfusion device | |
| CN206138406U (en) | Syringe needle dispenses with two -way filtering capability | |
| CN206138405U (en) | Syringe needle dispenses with one -way filtration | |
| CN208405371U (en) | Dispenser | |
| CN206534959U (en) | A kind of stopcock formula filtering injection needle with passage | |
| CN206315288U (en) | Double end matches somebody with somebody liquid syringe | |
| CN206120737U (en) | Safe type syringe needle that dispenses with one -way filtering capability | |
| CN206120739U (en) | Syringe needle dispenses with one -way filtering capability | |
| CN208200955U (en) | A kind of rapid blood connector suitable for CAR-T blood sampling | |
| CN213311729U (en) | Bottle stopper puncture needle device | |
| CN215386539U (en) | Special safe type pjncture needle and puncture suit in infusion port | |
| CN210020628U (en) | Needleless infusion joint | |
| RU2271834C1 (en) | Device for carrying apparatus-free membrane plasmapheresis according to single-needle scheme | |
| CN208611496U (en) | Multi-functional filter | |
| CN212699927U (en) | Precise filtering infusion apparatus with medicine dispensing connector | |
| CN202314654U (en) | Double-filtration blood return prevention infusion apparatus | |
| CN217489428U (en) | Blood transfusion device | |
| CN215653039U (en) | Novel normal saline tube sealing liquid device |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| CP03 | Change of name, title or address |
Address after: Building 52, 500 Binhai East Road, Muping District, Yantai City, Shandong Province, 264199 Patentee after: Shandong Baiao Stem Cell Biotechnology Co.,Ltd. Address before: Room 402, 4th floor, building B1, standard workshop community, Xi'an Modern Textile Industrial Park, Baqiao District, Xi'an City, Shaanxi Province 710024 Patentee before: Shaanxi Baiao Stem Cell Regenerative Medicine Co.,Ltd. |
|
| CP03 | Change of name, title or address | ||
| CP01 | Change in the name or title of a patent holder |
Address after: Building 52, 500 Binhai East Road, Muping District, Yantai City, Shandong Province, 264199 Patentee after: Shandong Baihong Stem Cell Biotechnology Co.,Ltd. Address before: Building 52, 500 Binhai East Road, Muping District, Yantai City, Shandong Province, 264199 Patentee before: Shandong Baiao Stem Cell Biotechnology Co.,Ltd. |
|
| CP01 | Change in the name or title of a patent holder |